Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 513-523
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.513
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.513
Table 1 Eosinophilic gastroenteritis severity upon presentation
Initial findings | Mild | Moderate | Severe | Complicated |
Clinical | ||||
Abdominal pain | Mild | Moderate | Severe | |
Vomiting | Mild (< 3/d) | Moderate (3-7/d) | protracted (> 8/d) | |
Diarrhea | < 6 BM/d | 6-12 BM/d | > 12 BM/d | |
Weight loss1[35] | Non-significant | 1 wk 1%-2% 1 mo 5% 3 mo 7.5% 6 mo 10% | 1 wk > 2% 1 mo > 5% 3 mo > 7.5% 6 mo > 10% | |
Laboratory | ||||
Alb, g/dL | > 3 | 2.5-3 | < 2.5 | |
HB, g/dL[36] | 9.5-11 | 8-9.5 | < 8 | |
AEC, cells/μL[37] | < 1500 | 1500-5000 | > 5000 | |
Radiologic | ||||
Ascites | None or mild | Moderate volume | Large volume | Perforation |
Intestinal wall thickening[38] | Mild (1-2 cm) Focal (< 10 cm) | Marked (> 2 cm), segmental (10-30 cm) | Sub-occlusion, extensive (> 30 cm) | Occlusion Intussusception |
Endoscopy | ||||
Mucosal inflammation[39] | Normal or mild erythema | Moderate | Severe with pseudo-polyps/bleeding | GOO Pyloric stenosis |
Histology | ||||
Structural damage2[34] | Minimal | Moderate | Severe |
Table 2 Published cases of eosinophilic gastroenteritis treated with budesonide
Ref. | Patient no. | Intestinal layer | Location | Previous treatment | Response |
Russel et al[52], 1994 | 1 | Mucosal | Ileum and cecum | Intolerant to steroids Failure of cromolyn sodium and mesalazine | Efficacy comparable to steroids over 5 mo |
Tan et al[53], 2001 | 1 | Full thickness with ascites | Antrum | Steroid dependent | Remission (+) over 2 yr |
Siewert et al[54], 2006 | 1 | Mucosal | Duodenum to ileum | None | Response (+) |
Lombardi et al[55], 2007 | 1 | Mucosal + submucosal | Ileum | Relapse after stopping budesonide and cromolyn sodium | Remission (+) on budesonide alone over 4 mo |
Elsing et al[56], 2007 | 1 | Muscular | Jejunum | Surgery + steroids for relapse | Remission (+) over 3 mo |
Shahzad et al[57], 2011 | 1 | Mucosal | Antrum + colon | None | Response (+) |
Busoni et al[58], 2011 | 5 | Mucosal | Lower + upper GI tract | Prednisone/methylprednisolone | Remission (+) |
Lombardi et al[59], 2011 | 1 | Muscular | Pyloric stenosis | Methylprednisolone | Remission (+) over 6 mo |
Müller et al[26], 2014 | 1 | Mucosal | Duodenum + colon + ileum | None | 50% response (combined with 6-food elimination diet) |
Wong et al[15], 2015 | 1 | Mucosal +/- serosal or muscular | - | None | Recurrent symptoms |
Table 3 Published cases of eosinophilic gastroenteritis treated with montelukast
Ref. | Patient no. | Intestinal layer | Location | Previous treatment | Response |
Neustrom et al[63], 1999 | 1 | Mucosal | Esophagus + stomach + small intestine | Failure of response to elimination diet, cromolyn sodium, ranitidine and hydroxyzine | Clinical and histologic response (+) |
Schwartz et al[64], 2001 | 1 | Serosal | Duodenum | Steroid dependent | Remission (+) over 4 wk |
Lu et al[65], 2003 | 2 | Mucosal | - | Steroid dependent | 1 → Not effective |
2 → Partial response with tapering of prednisone to 10 mg/d | |||||
Vanderhoof et al[66], 2003 | 8 | Mucosal | Esophagus (n = 4) Duodenum (n = 2) Colon (n = 2) | Failure of standard therapies | Clinical response (+) within 1 mo |
Copeland et al[9], 2004 | 1 | Mucosal | Stomach | Steroid refractory EGE (also receiving 6MP and 5ASA for UC) | Not effective |
Friesen et al[67], 2004 | 40 | Mucosal | Duodenum | None | Response (+) within 2 wk |
Quack et al[68], 2005 | 1 | Serosal | Ileum | Steroid dependent | Remission (+) over 2 yr |
Urek et al[21], 2006 | 1 | Serosal | Ileum | Steroid dependent | Response (+) within 4 wk |
De Maeyer et al[69], 2011 | 1 | - | - | Steroid dependent | Response (+) |
Tien et al[5], 2011 | 12 | Mucosal | Stomach + duodenum + colon + esophagus | 4 → None 8 → Steroid dependent | Remission (+) over 12 mo 4/8 → Successful steroid tapering 3/8 → Not effective 1/8 → Lost to follow-up |
Selva Kumar et al[70], 2011 | 1 | Mucosal | Small intestine | Unresponsive to standard therapy | Response (+) |
Müller et al[26], 2014 | 2 | Mucosal (+/- serosal or muscular) | Stomach + small intestine | 1 and 2 → Steroid dependent | 1 → Remission (+) in combination with low-dose prednisone 2 → Remission (+) (off steroids) |
Wong et al[15], 2015 | 2 | Mucosal (+/- serosal or muscular) | - | 1: Steroid dependent 2: None | Remission (+) for 36 mo (in combination with prednisone) Asymptomatic for 10 mo |
Table 4 Published cases of eosinophilic gastroenteritis treated with cromolyn sodium
Ref. | Patient no. | Intestinal layer | Location | Previous treatment | Response |
Moots et al[71], 1988 | 1 | Mucosal +/- muscular | Small intestine + colon | Prednisone, cyclophosphamide | Response (+) in 10 wk Maintenance over 2.5 yr |
Talley et al[4], 1990 | 3 | Mucosal | - | None | 1 → Response (+) 2 → No response |
Di Gioacchino et al[72], 1990 | 2 | Mucosal | Stomach + duodenum | None | Clinical and histologic response (+) after 4-5 mo |
Beishuizen et al[73], 1993 | 2 | Mucosal | Upper gastrointestinal tract | Steroids | Prolonged response (+) |
Van Dellen et al[74], 1994 | 1 | Mucosal | Stomach + duodenum | Elemental diet (poorly tolerated) | Response (+) |
Russel et al[52], 1994 | 1 | Mucosal | Ileum + colon | Steroid dependent | None (failure to taper steroids) |
Pérez-Millán et al[75], 1997 | 1 | Serosal | Duodenum | None | Response (+) over 6 mo |
Suzuki et al[76], 2003 | 1 | Mucosal | Stomach + duodenum | Targeted elimination diet (poorly tolerated) | Response (+) (in combination with ketotifene) |
Sheikh et al[77], 2009 | 3 | Mucosal Mucosal Mucosal +/- muscular | Esophagus + stomach + duodenum Stomach + duodenum + colon Esophagus + stomach + duodenum + colon | Steroid refractory None Steroid dependent | Not effective Partial response Response (+) with tapering of prednisone over 6 mo |
- Citation: Abou Rached A, El Hajj W. Eosinophilic gastroenteritis: Approach to diagnosis and management. World J Gastrointest Pharmacol Ther 2016; 7(4): 513-523
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/513.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.513